Westfield Capital Management Co. LP Increases Stock Holdings in Bio-Rad Laboratories, Inc. $BIO

Westfield Capital Management Co. LP boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,524 shares of the medical research company’s stock after buying an additional 16,019 shares during the period. Westfield Capital Management Co. LP owned approximately 0.57% of Bio-Rad Laboratories worth $43,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in BIO. Farther Finance Advisors LLC increased its holdings in shares of Bio-Rad Laboratories by 52.9% during the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 36 shares in the last quarter. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 24.0% during the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after purchasing an additional 40 shares during the last quarter. Frank Rimerman Advisors LLC grew its position in Bio-Rad Laboratories by 3.0% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 1,806 shares of the medical research company’s stock worth $436,000 after purchasing an additional 53 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in Bio-Rad Laboratories by 1.9% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,871 shares of the medical research company’s stock valued at $693,000 after purchasing an additional 54 shares in the last quarter. Finally, OneDigital Investment Advisors LLC raised its holdings in shares of Bio-Rad Laboratories by 1.9% in the third quarter. OneDigital Investment Advisors LLC now owns 2,954 shares of the medical research company’s stock worth $828,000 after buying an additional 55 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $275.28 on Friday. The firm has a market capitalization of $7.43 billion, a P/E ratio of 9.86 and a beta of 1.18. The stock has a 50-day simple moving average of $298.60 and a two-hundred day simple moving average of $301.16. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.06). The company had revenue of $693.20 million for the quarter, compared to analyst estimates of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The firm’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the business earned $2.90 earnings per share. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BIO shares. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Citigroup increased their price objective on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Wells Fargo & Company lifted their target price on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.